364 related articles for article (PubMed ID: 12827460)
21. Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients.
Brytting M; Mousavi-Jazi M; Boström L; Larsson M; Lunderberg J; Ljungman P; Ringdén O; Sundqvist VA
Transplantation; 1995 Nov; 60(9):961-5. PubMed ID: 7491701
[TBL] [Abstract][Full Text] [Related]
22. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus infection in renal transplant recipients.
Carstens J; Andersen HK; Spencer E; Madsen M
Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
[TBL] [Abstract][Full Text] [Related]
26. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
Fica A; Cervera C; Pérez N; Marcos MA; Ramírez J; Linares L; Soto G; Navasa M; Cofan F; Ricart MJ; Pérez-Villa F; Pumarola T; Moreno A
Transpl Infect Dis; 2007 Sep; 9(3):203-10. PubMed ID: 17511827
[TBL] [Abstract][Full Text] [Related]
28. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
Barkholt L; Linde A; Falk KI
Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
[TBL] [Abstract][Full Text] [Related]
29. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
Seehofer D; Rayes N; Tullius SG; Schmidt CA; Neumann UP; Radke C; Settmacher U; Müller AR; Steinmüller T; Neuhaus P
Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
[TBL] [Abstract][Full Text] [Related]
30. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
[TBL] [Abstract][Full Text] [Related]
32. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value.
Martín-Dávila P; Fortún J; Gutiérrez C; Martí-Belda P; Candelas A; Honrubia A; Barcena R; Martínez A; Puente A; de Vicente E; Moreno S
J Clin Virol; 2005 Jun; 33(2):138-44. PubMed ID: 15911429
[TBL] [Abstract][Full Text] [Related]
33. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection.
Mengoli C; Cusinato R; Biasolo MA; Cesaro S; Parolin C; Palù G
J Med Virol; 2004 Sep; 74(1):78-84. PubMed ID: 15258972
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
35. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
[TBL] [Abstract][Full Text] [Related]
36. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients.
Grossi P; Minoli L; Percivalle E; Irish W; Vigano M; Gerna G
Transplantation; 1995 Mar; 59(6):847-51. PubMed ID: 7701579
[TBL] [Abstract][Full Text] [Related]
37. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
[TBL] [Abstract][Full Text] [Related]
38. Human beta-herpesvirus interactions in solid organ transplant recipients.
Mendez JC; Dockrell DH; Espy MJ; Smith TF; Wilson JA; Harmsen WS; Ilstrup D; Paya CV
J Infect Dis; 2001 Jan; 183(2):179-184. PubMed ID: 11120923
[TBL] [Abstract][Full Text] [Related]
39. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients.
Sanghavi SK; Abu-Elmagd K; Keightley MC; St George K; Lewandowski K; Boes SS; Bullotta A; Dare R; Lassak M; Husain S; Kwak EJ; Paterson DL; Rinaldo CR
J Clin Virol; 2008 Aug; 42(4):335-42. PubMed ID: 18495527
[TBL] [Abstract][Full Text] [Related]
40. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
Gilbert C; Roy J; Belanger R; Delage R; Beliveau C; Demers C; Boivin G
Antimicrob Agents Chemother; 2001 Dec; 45(12):3669-71. PubMed ID: 11709367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
